

REMARKS/ARGUMENTS

Claims 1-6 and 8-22 are active in this application. Claim 1 is amended to incorporate the limitations of Claim 7, which is supported by the specification as originally filed, e.g. page 3. No new matter is believed to be added by virtue of this amendment.

The pending claims in this application are directed to a method of softening lines, relaxing skin, and/or relaxing facial features by topical application to one or more zones of the face or forehead marked with expression lines and/or to persons of a composition of adenosine or an adenosine derivative.

The rejections of Claims 1, 8, 21, and 22 as being anticipated by U.S. patent no. 6,423,327 ("Dobson") and Claims 1-2 as being anticipated by U.S. patent no. 3,978,213 ("Lapinet") are no longer applicable as Claim 1 has been amended to include the limitations of Claim 7, which was not listed in either rejection. Accordingly, withdrawal of both rejection under 35 USC 102 is requested.

Turning to the rejection of Claims 1-22 as being obvious in view of Dobson, the rejection is respectfully traversed because Dobson does not describe or suggest all of the claimed elements nor suggest using the composition in the manner as set forth in the claims. . Initially, it is noted that Dobson is acknowledged and discussed on page 6 of the present application.

Dobson describes the use of adenosine for "enhancement of skin condition[s]" such as those resulting from exposure to sun (see col. 2, lines 43-48). Dobson's method is based on the discovery "that adenosine stimulates DNA synthesis, increase protein synthesis, and increases cell size in cultures of human skin fibroblasts" (see col. 1, lines 37-41). Dobson does not describe the treatment of expression lines nor the relaxing effect on contractile fibroblasts as was discovered by the inventors of the present application.

Furthermore, while Dobson generally describes that the adenosine composition can be applied topically, it does so with additional reference to transdermal patches, oral, subdermal, intradermal, or intravenous administration routes (see col. 5, lines 10-29). Dobson does not describe nor provide any reasonable suggestion for applying a composition to certain zones marked with expression lines and/or persons having expression lines as claimed herein.

Furthermore, Dobson does not describe or reasonably suggest the specific intent of softening lines and/or relaxing skin and/or facial features as claimed. . Rather, Dobson, as discussed above, and disclosed in col. 2, lines 35-37 has the intent of enhancing a skin condition, which “means a noticeable decrease in the amount of wrinkling, roughness, dryness, laxity, sallowness, or pigmentary mottling in skin.” As the claimed method sets forth an intentional purpose whereas Dobson describe the use of adenosine compounds for a purpose other than that defined in the claims, the claims would not have been obvious in view of the Dobson disclosure.

Accordingly, withdrawal of this ground of rejection is requested.

Noting that the Examiner did not initial reference AW because a date had not been provided, Applicants submit herewith another Information Disclosure Statement listing this reference including a date. A copy of the reference is again provided for convenience.

Application No. 10/701,495
Reply to Office Action of June 2, 2005

Applicants request allowance of this case.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Richard L. Treanor
Registration No. 36,379

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)

Daniel J. Pereira, Ph.D.
Registration No. 45,518